<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VECTICAL - calcitriol ointment </strong><br>Galderma Laboratories, L.P.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use VECTICAL Ointment safely and effectively. See full prescribing information for VECTICAL Ointment. VECTICAL<span class="Sup">®</span> (calcitriol) OINTMENT 3 mcg/g<br>For topical use only<br>Initial U.S. Approval: 1978</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">VECTICAL Ointment is a vitamin D analog indicated for the topical treatment of mild to moderate plaque <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> in adults 18 years and older.  (<a href="#section-1">1</a>)</p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Apply VECTICAL Ointment to affected areas of the body twice daily.(<a href="#link_dose_and_admin">2</a>) The maximum weekly dose should not exceed 200 g. </p>
<p class="Highlighta">VECTICAL Ointment is not for oral, ophthalmic, or intravaginal use. </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Each gram of ointment contains 3 micrograms of calcitriol.  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li>None (<a href="#link_contraindications">4</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>If aberrations in parameters of calcium metabolism are noted discontinue VECTICAL Ointment until these normalize. (<a href="#undefined">5.1</a>)</li>
<li>Avoid excessive exposure of VECTICAL Ointment treated areas to either natural or artificial sunlight. (<a href="#undefined">5.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence ≥3%) were lab test abnormality, <span class="product-label-link" type="condition" conceptid="4298419" conceptname="Cloudy urine">urine abnormality</span>, <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, <span class="product-label-link" type="condition" conceptid="4215809" conceptname="Hypercalciuria">hypercalciuria</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>. (<a href="#undefined">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact: Galderma Laboratories, L.P. at 866-735-4137 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch<a href="http://">.</a></span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 7/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Indication</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Limitations of Use</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Effects on Calcium Metabolism</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Ultraviolet Light Exposure</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Unevaluated Uses</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-14.2" class="toc">16.2 Storage</a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Instructions for Use</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Adverse Reactions</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="link_indications_and_usage"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="Le34a41ac-528d-493a-ba28-c92116782efd"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Indication</h2>
<p class="First">VECTICAL Ointment is indicated for the topical treatment of mild to moderate plaque <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> in adults 18 years and older.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Lea6dab9d-5275-4d04-8001-8a026a65174d"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Limitations of Use</h2>
<p class="First">VECTICAL Ointment should not be applied to the eyes, lips, or facial skin.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="link_dose_and_admin"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Apply VECTICAL Ointment to affected areas twice daily, morning and evening. The maximum weekly dose should not exceed 200 grams.</p>
<p>VECTICAL Ointment is not for oral, ophthalmic or intravaginal use.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="link_doseform_strength"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Each gram of ointment contains 3 micrograms (mcg/g) of calcitriol.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="link_contraindications"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="link_warn_and_precautions"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First"><br></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>5.1 Effects on Calcium Metabolism</h2>
<p class="First">In controlled clinical trails with VECTICAL Ointment, among subjects having laboratory monitoring, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> was observed in 24% (18/74) of subjects exposed to active drug and in 16% (13/79) of subjects exposed to vehicle. However, the increases in calcium and albumin-adjusted calcium levels were less than 10% above the upper limit of normal.</p>
<p>If aberrations in parameters of calcium metabolism occur, treatment should be discontinued until these parameters have normalized. The effects of VECTICAL Ointment on calcium metabolism following treatment durations greater than 52 weeks have not been evaluated. Increased absorption may occur with occlusive use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>5.2 Ultraviolet Light Exposure</h2>
<p class="First">Animal data suggest that the vehicle of VECTICAL Ointment may enhance the ability of ultraviolet radiation (UVR) to induce <span class="product-label-link" type="condition" conceptid="135777" conceptname="Neoplasm of uncertain behavior of skin">skin tumors</span>. [see Carcinogenesis, Mutagenesis, Impairment of Fertility (13.1)]</p>
<p>Subjects who apply VECTICAL Ointment to exposed skin should avoid excessive exposure of the treated areas to either natural or artificial sunlight, including tanning booths and sun lamps. Physicians may wish to limit or avoid use of phototherapy in patients who use VECTICAL Ointment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2>5.3 Unevaluated Uses</h2>
<p class="First">The safety and effectiveness of VECTICAL Ointment in patients with known or suspected disorders of calcium metabolism have not been evaluated.</p>
<p>The safety and effectiveness of VECTICAL Ointment in patients with erythrodermic, exfoliative, or <span class="product-label-link" type="condition" conceptid="4063434" conceptname="Pustular psoriasis">pustular psoriasis</span> have not been evaluated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="link_adverse_react"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">VECTICAL Ointment was studied in two vehicle-controlled studies (419 subjects), and in one open label study (324 subjects). The table below describes exposure to VECTICAL Ointment in 743 subjects, including 239 exposed for 6 months and 116 exposed for one year.</p>
<p>Four hundred and nineteen subjects were treated with VECTICAL Ointment twice daily for 8 weeks. The population included subjects ages 13 to 87, males (284) and females (135), Caucasians (372) and non-Caucasians (47); with mild (105) to moderate (313) chronic plaque <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>.</p>
<p><img alt="6-1-table" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a1567da9-af74-4afd-9ac5-8b53ec5d7cbf&amp;name=6-1-table.jpg"></p>
<p>Among subjects having laboratory monitoring, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> was observed in 24% (18/74) of subjects exposed to active drug and in 16% (13/79) of subjects exposed to vehicle, however the elevations were less than 10% above the upper limit of normal [<span class="Italics">see WARNINGS AND PRECAUTIONS (5.1)</span>]</p>
<p>The open label study enrolled 324 subjects with <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> who were then treated for up to 52 weeks. Adverse events reported at a rate of greater than or equal to 3% of subjects treated with VECTICAL Ointment were lab test abnormality (8%), <span class="product-label-link" type="condition" conceptid="4298419" conceptname="Cloudy urine">urine abnormality</span> (4%), <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> (4%), <span class="product-label-link" type="condition" conceptid="4215809" conceptname="Hypercalciuria">hypercalciuria</span> (3%), and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (3%). <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Kidney stones</span> were reported in 3 subjects and confirmed in two.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during world-wide post-approval use of VECTICAL Ointment: acute <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span> <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4010479" conceptname="Sensation of burning of skin">skin burning sensation</span>, and skin <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">VECTICAL Ointment should be used with caution in patients receiving medications known to increase the serum calcium level, such as thiazide diuretics. Caution should also be exercised in patients receiving calcium supplements or high doses of vitamin D. [<span class="Italics">see WARNINGS AND PRECAUTIONS (5.1)</span>].</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<p class="First"><br></p>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Teratogenic Effects: Pregnancy Category C.</p>
<p>VECTICAL Ointment contains calcitriol which has been shown to be fetotoxic. There are no adequate and well-controlled studies for VECTICAL Ointment in pregnant women. VECTICAL Ointment should be used during pregnancy only if the potential benefit to the patient justifies the potential risk to the fetus.</p>
<p><span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> studies with calcitriol were performed in which rats were treated orally at dosages up to 0.9 mcg/kg/day (5.4 mcg/m<span class="Sup">2</span>/day) and in which rabbits received topical application of calcitriol ointment (3 ppm) to 6.4% of the body surface area. No effects on reproductive or fetal parameters were observed in rats. In rabbits, topically applied calcitriol induced a significantly elevated mean post-implantation loss and an increased incidence of minor skeletal abnormalities due to retarded ossification of the pubic bones. A slightly increased incidence of skeletal variation (extra 13<span class="Sup">th</span> rib, reduced ossification of epiphyses) was also observed. These effects may have been secondary to maternal toxicity. Based on the recommended human dose and instructions for use, it is not possible to calculate human dose equivalents for animal exposures in these studies.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether calcitriol is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when VECTICAL Ointment is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of VECTICAL Ointment did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported experience has not identified differences in responses between the elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Topically applied calcitriol can be absorbed in sufficient amounts to produce systemic effects [<span class="Italics">see WARNINGS AND PRECAUTIONS (5.1)</span>]</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">VECTICAL (calcitriol) Ointment 3 mcg/g is a vitamin D analog intended for topical application to the skin. The chemical name of the active ingredient is (5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1α,3β,25-triol. The structural formula is:</p>
<p><img alt="chem-struct" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a1567da9-af74-4afd-9ac5-8b53ec5d7cbf&amp;name=chem-struct.jpg"></p>
<p>Calcitriol is a white or almost white crystalline solid. It is practically insoluble in water, soluble in alcohol and in fatty oils. The molecular formula is C<span class="Sub">27</span>H<span class="Sub">44</span>O<span class="Sub">3</span>, and the molecular weight is 416.64.</p>
<p>VECTICAL Ointment is a translucent ointment containing 3 mcg/g (0.0003% w/w) of calcitriol, packaged in aluminum tubes with screw caps. Other components of the ointment are mineral oil, dl-α-tocopherol, and white petrolatum.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<p class="First">The contribution to efficacy of individual components of the vehicle has not been established.</p>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of action of calcitriol in the treatment of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> has not been established.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacokinetics</h2>
<p class="First">The systemic exposure of calcitriol was assessed in subjects with chronic, plaque <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>. In the pivotal pharmacokinetic/pharmacodynamic study, calcitriol ointment 3 mcg/g, was applied twice daily for 21 days (for a total dose of 30 g/day) to 35% of the body surface area (psoriatic + surrounding healthy skin) of subjects with at least 25% of body surface area involvement. At Day 21, the geometric mean plasma concentration values of C<span class="Sub">max</span> increased by approximately 36% over baseline and the geometric mean value of AUC<span class="Sub">(0 – 12 hr)</span> increased by 44%. There was no correlation between the elevated calcitriol levels and the pharmacodynamic parameters of serum albumin adjusted calcium, serum phosphorus, urinary calcium and urinary phosphorus.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="BE6A517E-4EB3-4A82-B825-31D933D92900"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<p class="First"><br></p>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">When calcitriol was applied topically to mice for up to 24 months, no significant changes in tumor incidence were observed. Concentrations of calcitriol in ointment base of 0 (vehicle control), 0.3, 0.6 and 1.0 ppm were evaluated.</p>
<p>A two-year carcinogenicity study was conducted in which calcitriol was orally administered to rats at dosages of approximately 0.005, 0.03, and 0.1 mcg/kg/day (0.03, 0.18, and 0.6 mcg/m<span class="Sup">2</span>/day, respectively). The incidence of benign <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytomas</span> was significantly increased in female rats. No other significant differences in tumor incidence data were observed.</p>
<p>In a study in which albino hairless mice were exposed to both ultra-violet radiation (UVR) and topically applied calcitriol ointment, a reduction in the time required for UVR to induce the formation of <span class="product-label-link" type="condition" conceptid="135777" conceptname="Neoplasm of uncertain behavior of skin">skin tumors</span> was observed in all groups that received the ointment base, including the vehicle-treated control group, relative to animals that received no ointment but which were exposed to UVR. The time required for UVR to induce the formation of <span class="product-label-link" type="condition" conceptid="135777" conceptname="Neoplasm of uncertain behavior of skin">skin tumors</span> did not differ between animals that received plain vehicle and those that received vehicle that contained calcitriol. Concentrations of calcitriol in ointment base of 0 (vehicle control), 0.3, 0.6 and 1.0 ppm were evaluated. These data suggest that the vehicle of VECTICAL Ointment may enhance the ability of UVR to induce <span class="product-label-link" type="condition" conceptid="135777" conceptname="Neoplasm of uncertain behavior of skin">skin tumors</span>.</p>
<p>Calcitriol did not elicit genotoxic effects in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> TK locus assay.</p>
<p>Studies in which male and female rats received oral doses of calcitriol of up to 0.6 mcg/kg/day (3.6 mcg/m<span class="Sup">2</span>/day) indicated no impairment of fertility or general reproductive performance.</p>
<p>Based upon the recommended human dose and instructions for use, it is not possible to calculate human dose equivalents for animal exposure in these studies.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">In two, multicenter, double-blind, vehicle-controlled studies, a total of 839 subjects with <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> rated "mild" or "moderate" using an investigator global assessment scale were treated twice daily for 8 weeks. Subjects were randomized in a 1:1 ratio to receive either VECTICAL Ointment or vehicle ointment. The mean age of the subjects was 48 years and 66% were male; most subjects were rated "moderate" at baseline.</p>
<p>Success was defined as "Clear or Minimal" (up to light red or pink in coloration, surface dryness with some white coloration, and slight elevation above normal skin) with at least a 2-grade change from baseline. The success rates are displayed in the table.</p>
<p><img alt="14-table" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a1567da9-af74-4afd-9ac5-8b53ec5d7cbf&amp;name=14-table.jpg"></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><br></p>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">VECTICAL Ointment 3 mcg/g is available in collapsible aluminum tubes of the following package sizes:</p>
<ul class="Disc"><li><p class="First">100 g tube (NDC 0299-2012-10)</p></li></ul>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.2"></a><p></p>
<h2>16.2 Storage</h2>
<p class="First">Store at Controlled Room temperature 68° - 77°F (20° - 25°C) with excursions permitted between 59° - 86°F (15° - 30°C). [See USP Controlled Room Temperature.] Do not freeze or refrigerate.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.</p>
<p>Patients using VECTICAL Ointment should receive the following information:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1"></a><p></p>
<h2>17.1 Instructions for Use</h2>
<p class="First">This medication is to be used as directed by the physician. It is for external use only. This medication is to be applied only to areas of the skin affected by <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, as directed. It should be gently rubbed into the skin so that no medication remains visible.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.2"></a><p></p>
<h2>17.2 Adverse Reactions</h2>
<p class="First">Patients should report any signs of adverse reactions to their physician.</p>
<p><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact: Galderma Laboratories, L.P. at 1-866-735-4137 or FDA at 1-800-FDA-1088 or go to <span class="Italics">www.fda.gov/medwatch</span></span></p>
<p>U.S. Patent No. 7,749,986</p>
<p>Marketed by:<br>Galderma Laboratories L.P.<br>Fort Worth, Texas 76177 USA</p>
<p>Manufactured by:<br>G Production Inc.<br>Baie d’Urfé, QC, H9X 3S4 Canada</p>
<p>Made in Canada.<br>GALDERMA is a registered trademark.<br>P51460-4</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PACKAGE LABEL</h1>
<p class="First"></p>
<p><img alt="p51449-3 100g tube label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a1567da9-af74-4afd-9ac5-8b53ec5d7cbf&amp;name=p51449-3-100g-tube-lbl.jpg"></p>
<p><span class="Bold">NDC</span> 0299-2012-10<br><br><span class="Bold">Rx only</span><br><br><span class="Bold">Vectical<span class="Sup">®</span><br>(calcitriol) Ointment 3 mcg/g</span><br><span class="Bold">FOR TOPICAL USE ONLY</span><br><br><span class="Bold">NET WT. 100 g</span><br><br><span class="Bold">GALDERMA</span><br><br><span class="Bold">For topical use only. Not for ophthalmic, oral or intravaginal use.</span><br><br><span class="Bold">Usual dosage:</span> Apply to affected areas twice daily.<br><br>See package insert for complete prescribing information.<br><br><span class="Bold">Each gram contains:</span> calcitriol 3 mcg in an ointment base consisting of mineral oil, dl-α-tocopherol, and white petrolatum.<br><br><span class="Bold">Storage:</span> Store at controlled room temperature 68° - 77°F (20° - 25°C) with excursions permitted between 59° - 86°F (15° - 30°C). Do not freeze or refrigerate. Lot no. and exp. date on crimp.</p>
<p>US Patent No. 7,749,986<br><br>Marketed by:<br>GALDERMA LABORATORIES, L.P.<br>Fort Worth, Texas 76177 USA<br>Manufactured by:<br>G Production Inc.<br>Baie d’Urfé, QC, H9X 3S4 Canada<br>Made in Canada.<br>GALDERMA is a registered trademark.<br>P51449-3</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VECTICAL 		
					</strong><br><span class="contentTableReg">calcitriol ointment</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0299-2012</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CALCITRIOL</strong> (CALCITRIOL) </td>
<td class="formItem">CALCITRIOL</td>
<td class="formItem">3 ug  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mineral oil</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>.ALPHA.-TOCOPHEROL, DL-</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Petrolatum</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0299-2012-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0299-2012-05</td>
<td class="formItem">5 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022087</td>
<td class="formItem">02/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Galderma Laboratories, L.P.
							(047350186)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">G Production Inc.</td>
<td class="formItem"></td>
<td class="formItem">251676961</td>
<td class="formItem">manufacture(0299-2012)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d76513fe-dfcd-49a7-9df2-70dede53de18</div>
<div>Set id: a1567da9-af74-4afd-9ac5-8b53ec5d7cbf</div>
<div>Version: 8</div>
<div>Effective Time: 20141001</div>
</div>
</div> <div class="DistributorName">Galderma Laboratories, L.P.</div></p>
</body></html>
